Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 14/20 | 0.58 |
| ▸ | FPR2 | P25090 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11984631 | 0.90 | FOLH1 (0.64) | NAALAD2FOLH1 | |
| SCHEMBL13538922 | 0.89 | NAALAD2 (0.78) | NAALAD2FOLH1 | |
| SCHEMBL14116846 | 0.88 | NAALAD2 (0.77) | NAALAD2FOLH1FPR2 | |
| SCHEMBL11941426 | 0.88 | NAALAD2 (0.77) | NAALAD2FOLH1FPR2 | |
| SCHEMBL4132676 | 0.88 | NAALAD2 (0.77) | NAALAD2FOLH1FPR2 | |
| SCHEMBL4317844 | 0.88 | NAALAD2 (0.77) | NAALAD2FOLH1FPR2 | |
| SCHEMBL11936648 | 0.88 | NAALAD2 (0.77) | NAALAD2FOLH1FPR2 | |
| SCHEMBL4317843 | 0.88 | NAALAD2 (0.77) | NAALAD2FOLH1FPR2 | |
| SCHEMBL11940476 | 0.88 | FOLH1 (0.64) | NAALAD2FOLH1 | |
| SCHEMBL14117023 | 0.88 | NAALAD2 (0.61) | NAALAD2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | GEORGETOWN UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-8227634-B2 | Imaging agents and methods of imaging NAALADase or PSMA | POMPER MARTIN GILBERT (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2008121949-A1 | CANCER CELL TARGETING USING NANOPARTICLES | BIND BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-7408079-B2 | Imaging prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | FOLH1, DNPEP, NAALAD2 | NAALAD2 3/4885FOLH1 1/4885FPR2 3382/4885 |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | NAALAD2 3/4885FOLH1 1/4885FPR2 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.